alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### National Foundation of the Arts and Humanities

###### National Endowment for the Arts

# ACTION:

Notice.

# SUMMARY:

This notice announces the membership of the National Endowment for the Arts (NEA) Senior Executive Service (SES) Performance Review Board (PRB).

# DATES:

*Applicable:*                         November 2, 2017.                    

# ADDRESSES:

Send comments concerning this notice to: National Endowment for the Arts, 400 7th Street SW., Washington, DC 20506.

# FOR FURTHER INFORMATION CONTACT:

                        Craig McCord Sr. by telephone at (202) 682-5473 or by email at                         *mccordc@arts.gov.*

# SUPPLEMENTARY INFORMATION:

4314(c)(1) through (5) of Title 5, U.S.C., requires each agency to establish, in accordance with regulations prescribed by the Office of Personnel Management, one or more SES Performance Review Boards. The Board shall review and evaluate the initial appraisal of a senior executive's performance by the supervisor, along with any response by the senior executive, and make recommendations to the appointing authority relative to the performance of the senior executive.

The following persons have been selected to serve on the Performance Review Board of the National Endowment for the Arts (NEA):

Ann Eilers-Deputy Chairman for Management and Budget

Michael Griffin—Chief of Staff

Ronald Luczak—Office of Security, Facilities, and Logistics Director, Department of Education

Dated: November 1, 2017.

Jane Chu,

Chairman.

Dated: November 6, 2017.

Jillian Miller,

Director of Guidelines and Panel Operations, Administrative Services, National Endowment for the Arts.

[FR Doc. 2017-24374 Filed 11-8-17; 8:45 am]

BILLING CODE P
#### UNITED STATES of America, Plaintiff-Appellee, v. Salvador VACA, Defendant-Appellant.

No. 10-1164.

United States Court of Appeals, Seventh Circuit.

Submitted Nov. 17, 2010.

Decided Nov. 18, 2010.

Sheri H. Mecklenburg, Office of the United States Attorney, Chicago, IL, for Plaintiff-Appellee.

Richard H. Parsons, Office of the Federal Public Defender, Peoria, IL, A. Brian Threlkeld, Office of the Federal Public Defender, Urbana, IL, for Defendant-Appellant.

Before JOHN L. COFFEY, Circuit Judge, JOEL M. FLAUM, Circuit Judge and KENNETH F. RIPPLE, Circuit Judge.

ORDER

Salvador Vaca brokered a deal for his coconspirator to purchase five kilograms of cocaine from government informants. He later pleaded guilty to conspiring to possess with intent to distribute cocaine in violation of 21 U.S.C. §§ 841(a)(1), 846, and the district court sentenced him to the statutory minimum of 120 months’ imprisonment. Vaca’s appointed counsel on appeal has filed a motion to withdraw under *Anders v. California,*386 U.S. 738, 87 S.Ct. 1396, 18 L.Ed.2d 493 (1967), contending that any challenge to Vaca’s sentence would be frivolous. Vaca has not accepted our invitation to respond to counsel’s motion, *see*Cir R. 51(b). We limit our review to the potential issues identified in counsel’s facially adequate brief. *See United States v. Schuh,*289 F.3d 968, 973-74 (7th Cir.2002).

Because Vaca does not challenge his conviction or seek to withdraw his guilty plea, counsel correctly forgoes discussion of challenges to the voluntariness of the plea or the adequacy of the plea colloquy. *See United States v. Knox,*287 F.3d 667, 670-71 (7th Cir.2002).

Counsel first considers whether Vaca could challenge the reasonableness of his sentence. We agree with counsel that any such challenge would be frivolous. The district court properly assessed Vaca’s guidelines range as 120-135 months’ imprisonment (based on an offense level of 32 for distributing 5-15 kilograms of cocaine, a 3-level decrease for acceptance of responsibility, a criminal history category of III, and a statutory minimum of 120 months.) A sentence that is within the guidelines range is presumptively reasonable, *see Rita v. United States,*551 U.S. 338, 350-51, 127 S.Ct. 2456, 168 L.Ed.2d 203 (2007), and counsel identifies no possible challenge to disturb the presumption.

*77Counsel next assesses whether the district court adequately considered the sentencing factors under 18 U.S.C. § 3553(a), but properly concludes that any such challenge would be frivolous. The court’s evaluation of the § 3553(a) factors noted that brokering a deal for cocaine was a serious offense and that Vaca’s prior convictions were not merely isolated and aberrant incidents. The court also noted Vaca’s significant substance-abuse history, his education, and the hardship his incarceration will present for his daughters.

Counsel’s motion to withdraw is GRANTED and the appeal is DISMISSED.
I 

117TH CONGRESS 

1ST SESSION H. R. 2868 

To amend title XIX of the Social Security Act to prohibit additional rebates 

under the Medicaid program for certain noninnovator multiple source drugs. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 28, 2021 

Mr. BUTTERFIELD (for himself and Mr. LONG) introduced the following bill; 

which was referred to the Committee on Energy and Commerce 

A BILL 

To amend title XIX of the Social Security Act to prohibit 

additional rebates under the Medicaid program for certain noninnovator multiple source drugs. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Protecting Access to 

5 Affordable Medicines Act of 2021’’. 

6 SEC. 2. PROHIBITION ON ADDITIONAL REBATE UNDER 

7 MEDICAID FOR CERTAIN NONINNOVATOR 

8 MULTIPLE SOURCE DRUGS. 

9 Section 1927(c)(3)(C) of the Social Security Act (42 

10 U.S.C. 1396r–8(c)(3)(C)) is amended— 


pbinns on DSKJLVW7X2PROD with BILLS
2 

•HR 2868 IH

1 (1) in clause (i), by striking ‘‘The amount’’ and 

2 inserting ‘‘Subject to clause (v), the amount’’; and 

3 (2) by adding at the end the following new 

4 clause: 

5 ‘‘(v) PROHIBITION ON ADDITIONAL

6 REBATE FOR CERTAIN NONINNOVATOR

7 MULTIPLE SOURCE DRUGS.—With respect 

8 to a rebate period beginning on or after 

9 January 1, 2022, and a dosage form and 

10 strength of a covered outpatient drug de11 scribed in clause (i), the amount of the re12 bate specified in subparagraph (A) for 

13 such dosage form and strength for such re14 bate period may not be increased if the av15 erage manufacturer price for a unit of 

16 such dosage form and strength for such re17 bate period is less than $1.’’. 

Æ 


pbinns on DSKJLVW7X2PROD with BILLS
{"version":"1.0","provider_name":"Federal Maritime Commission","provider_url":"https:\/\/www.fmc.gov","author_name":"Catie-Megan Moran","author_url":"https:\/\/www.fmc.gov\/author\/cmoranfmc-gov\/","title":"Applicants December 21, 2020","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"W6WW3QZbVX\"><a href=\"\/oti\/applicants-december-21-2020\/\">Applicants December 21, 2020<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"\/oti\/applicants-december-21-2020\/embed\/#?secret=W6WW3QZbVX\" width=\"600\" height=\"338\" title=\"“Applicants December 21, 2020” — Federal Maritime Commission\" data-secret=\"W6WW3QZbVX\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/*! This file is auto-generated *\/\n!function(c,l){\"use strict\";var e=!1,o=!1;if(l.querySelector)if(c.addEventListener)e=!0;if(c.wp=c.wp||{},c.wp.receiveEmbedMessage);else if(c.wp.receiveEmbedMessage=function(e){var t=e.data;if(!t);else if(!(t.secret||t.message||t.value));else if(\/[^a-zA-Z0-9]\/.test(t.secret));else{for(var r,s,a,i=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),n=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),o=0;o<n.length;o++)n[o].style.display=\"none\";for(o=0;o<i.length;o++)if(r=i[o],e.source!==r.contentWindow);else{if(r.removeAttribute(\"style\"),\"height\"===t.message){if(1e3<(s=parseInt(t.value,10)))s=1e3;else if(~~s<200)s=200;r.height=s}if(\"link\"===t.message)if(s=l.createElement(\"a\"),a=l.createElement(\"a\"),s.href=r.getAttribute(\"src\"),a.href=t.value,a.host===s.host)if(l.activeElement===r)c.top.location.href=t.value}}},e)c.addEventListener(\"message\",c.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",t,!1),c.addEventListener(\"load\",t,!1);function t(){if(o);else{o=!0;for(var e,t,r,s=-1!==navigator.appVersion.indexOf(\"MSIE 10\"),a=!!navigator.userAgent.match(\/Trident.*rv:11\\.\/),i=l.querySelectorAll(\"iframe.wp-embedded-content\"),n=0;n<i.length;n++){if(!(r=(t=i[n]).getAttribute(\"data-secret\")))r=Math.random().toString(36).substr(2,10),t.src+=\"#?secret=\"+r,t.setAttribute(\"data-secret\",r);if(s||a)(e=t.cloneNode(!0)).removeAttribute(\"security\"),t.parentNode.replaceChild(e,t);t.contentWindow.postMessage({message:\"ready\",secret:r},\"*\")}}}}(window,document);\n<\/script>\n"}
BERNARD WHITE,

Appellant,

v.

STATE OF FLORIDA,

Appellee.

IN THE DISTRICT COURT OF APPEAL

FIRST DISTRICT, STATE OF FLORIDA

NOT FINAL UNTIL TIME EXPIRES TO 

FILE MOTION FOR REHEARING AND 

DISPOSITION THEREOF IF FILED

CASE NO. 1D14-4298

_____________________________/

Opinion filed September 5, 2017.

An appeal from the Circuit Court for Duval County.

Mallory D. Cooper, Judge.

Andy Thomas, Public Defender, and Glen P. Gifford, Assistant Public Defender, 

Tallahassee, for Appellant.

Pamela Jo Bondi, Attorney General, and Thomas H. Duffy, Assistant Attorney 

General, Tallahassee, for Appellee.

ON REMAND FROM THE SUPREME COURT OF FLORIDA

PER CURIAM.

In accordance with instructions from the Florida Supreme Court, this cause 

is remanded for resentencing in conformance with sections 775.082, 921.1401, and 

921.1402, Florida Statutes. See Kelsey v. State, 206 So. 3d 5 (Fla. 2016).

ROBERTS, KELSEY, and M.K. THOMAS, JJ., CONCUR.
{"version":"1.0","provider_name":"Federal Maritime Commission","provider_url":"https:\/\/www.fmc.gov","author_name":"Catie-Megan Moran","author_url":"https:\/\/www.fmc.gov\/author\/cmoranfmc-gov\/","title":"Fact Finding 29","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"Ohxql4gcdc\"><a href=\"\/fact-finding-29\/\">Fact Finding 29<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"\/fact-finding-29\/embed\/#?secret=Ohxql4gcdc\" width=\"600\" height=\"338\" title=\"“Fact Finding 29” — Federal Maritime Commission\" data-secret=\"Ohxql4gcdc\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/*! This file is auto-generated *\/\n!function(c,l){\"use strict\";var e=!1,o=!1;if(l.querySelector)if(c.addEventListener)e=!0;if(c.wp=c.wp||{},c.wp.receiveEmbedMessage);else if(c.wp.receiveEmbedMessage=function(e){var t=e.data;if(!t);else if(!(t.secret||t.message||t.value));else if(\/[^a-zA-Z0-9]\/.test(t.secret));else{for(var r,s,a,i=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),n=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),o=0;o<n.length;o++)n[o].style.display=\"none\";for(o=0;o<i.length;o++)if(r=i[o],e.source!==r.contentWindow);else{if(r.removeAttribute(\"style\"),\"height\"===t.message){if(1e3<(s=parseInt(t.value,10)))s=1e3;else if(~~s<200)s=200;r.height=s}if(\"link\"===t.message)if(s=l.createElement(\"a\"),a=l.createElement(\"a\"),s.href=r.getAttribute(\"src\"),a.href=t.value,a.host===s.host)if(l.activeElement===r)c.top.location.href=t.value}}},e)c.addEventListener(\"message\",c.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",t,!1),c.addEventListener(\"load\",t,!1);function t(){if(o);else{o=!0;for(var e,t,r,s=-1!==navigator.appVersion.indexOf(\"MSIE 10\"),a=!!navigator.userAgent.match(\/Trident.*rv:11\\.\/),i=l.querySelectorAll(\"iframe.wp-embedded-content\"),n=0;n<i.length;n++){if(!(r=(t=i[n]).getAttribute(\"data-secret\")))r=Math.random().toString(36).substr(2,10),t.src+=\"#?secret=\"+r,t.setAttribute(\"data-secret\",r);if(s||a)(e=t.cloneNode(!0)).removeAttribute(\"security\"),t.parentNode.replaceChild(e,t);t.contentWindow.postMessage({message:\"ready\",secret:r},\"*\")}}}}(window,document);\n<\/script>\n"}
I 

117TH CONGRESS 

1ST SESSION H. R. 2831 

To amend the Federal Food, Drug, and Cosmetic Act to provide for the 

prompt approval of drugs when safety information is added to labeling, 

and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 26, 2021 

Ms. BARRAGA ́N introduced the following bill; which was referred to the 

Committee on Energy and Commerce 

A BILL 

To amend the Federal Food, Drug, and Cosmetic Act to 

provide for the prompt approval of drugs when safety 

information is added to labeling, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Prompt Approval of 

5 Safe Generic Drugs Act’’. 

6 SEC. 2. HEADING. 

7 Section 505 of the Federal Food, Drug, and Cosmetic 

8 Act (21 U.S.C. 355) is amended by adding at the end the 

9 following: 


pamtmann on DSKBC07HB2PROD with BILLS
2 

•HR 2831 IH

1 ‘‘(z) PROMPT APPROVAL OF DRUGS WHEN SAFETY

2 INFORMATION IS ADDED TO LABELING.— 

3 ‘‘(1) GENERAL RULE.—A drug for which an ap4 plication has been submitted or approved under sub5 section (b)(2) or (j) shall not be considered ineligible 

6 for approval under this section or misbranded under 

7 section 502 on the basis that the labeling of the 

8 drug omits safety information, including contra9 indications, warnings, precautions, dosing, adminis10 tration, or other information pertaining to safety, 

11 when the omitted safety information is protected by 

12 exclusivity under clause (iii) or (iv) of subsection 

13 (c)(3)(E), clause (iii) or (iv) of subsection (j)(5)(F), 

14 or section 527(a), or by an extension of such exclu15 sivity under section 505A or 505E. 

16 ‘‘(2) LABELING.—Notwithstanding clauses (iii) 

17 and (iv) of subsection (c)(3)(E), clauses (iii) and (iv) 

18 of subsection (j)(5)(F), or section 527, the Secretary 

19 shall require that the labeling of a drug approved 

20 pursuant to an application submitted under sub21 section (b)(2) or (j) that omits safety information 

22 described in paragraph (1) include a statement of 

23 any appropriate safety information that the Sec24 retary considers necessary to assure safe use. 


pamtmann on DSKBC07HB2PROD with BILLS
3 

•HR 2831 IH

1 ‘‘(3) AVAILABILITY AND SCOPE OF EXCLU2 SIVITY.—This subsection does not affect— 

3 ‘‘(A) the availability or scope of exclusivity 

4 or an extension of exclusivity described in sub5 paragraph (A) or (B) of section 505A(o)(3); 

6 ‘‘(B) the question of the eligibility for ap7 proval under this section of any application de8 scribed in subsection (b)(2) or (j) that omits 

9 any other aspect of labeling protected by exclu10 sivity under— 

11 ‘‘(i) clause (iii) or (iv) of subsection 

12 (c)(3)(E); 

13 ‘‘(ii) clause (iii) or (iv) of subsection 

14 (j)(5)(F); or 

15 ‘‘(iii) section 527(a); or 

16 ‘‘(C) except as expressly provided in para17 graphs (1) and (2), the operation of this section 

18 or section 527.’’. 

Æ 


pamtmann on DSKBC07HB2PROD with BILLS
#### Ernesto PACHECO-PACHECO, Petitioner, v. Michael B. MUKASEY, Attorney General, Respondent.

No. 04-72850.

United States Court of Appeals, Ninth Circuit.

Submitted April 22, 2008.*

Filed May 6, 2008.

Ernesto Pacheco-Pacheco, pro se.

Cindy S. Fender, Michelle E. Gorden Latour, Michele Y.F. Sarko, U.S. Department of Justice Civil Div./Office of Immigration Lit., Washington, DC, Ronald E. Lefevre, Office of the District Counsel Department of Homeland Security, San Francisco, CA, for Respondent.

Before: GRABER, FISHER, and BERZON, Circuit Judges.

*

 The panel unanimously finds this case suitable for decision without oral argument. *See*Fed. R.App. P. 34(a)(2).

MEMORANDUM **

Ernesto Pacheco-Pacheco, a native and citizen of Mexico, petitions pro se for review of the Board of Immigration Appeals’ (“BIA”) order dismissing his appeal from an immigration judge’s decision denying his application for asylum, withholding of removal, and protection under the Convention Against Torture. We have jurisdiction under 8 U.S.C. § 1252. Petitioner has waived any challenge to the BIA’s order because he failed to raise any claims in his opening brief. *See Martinez-Serrano v. INS,*94 F.3d 1256, 1259-60 (9th Cir.1996).

PETITION FOR REVIEW DENIED.

**

 This disposition is not appropriate for publication and is not precedent except as provided by 9th Cir. R. 36-3.
Exhibit
32.1





CERTIFICATION




Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002


(Subsections
(a) and (b) of Section 1350, Chapter 63 of Title 18, United States
Code)




Pursuant
to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of
section 1350, chapter 63 of title 18, United States Code), each of the
undersigned officers of China Auto Logistics Inc., a Nevada corporation (the
“Company”), does hereby
certify, to such officer’s knowledge, that:




The
Annual Report on Form 10-K for the year ended December 31, 2008 (the “Form 10-K”) of the Company
fully complies with the requirements of section 13(a) or 15(d) of the Securities
Exchange Act of 1934, and information contained in the Form 10-K fairly
presents, in all material respects, the financial condition and results of
operations of the Company.





Date: March
30, 2009


/s/  Tong
  ShipingTong
      ShipingChief
      Executive Officer





Date:
March 30, 2009


/s/ Wang
      XinweiWang XinweiChief
      Financial Officer





A signed
original of this written statement required by Section 906 has been provided to
the Company and will be retained by the Company and furnished to the Securities
and Exchange Commission or its staff upon request.
Exhibit 32.2

                       CERTIFICATION PURSUANT TO
                         18 U.S.C. SECTION 1350,
                         AS ADOPTED PURSUANT TO
              SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

    In connection with the Quarterly Report of BF Acquisition Group V,
Inc. (the "Company") on Form 10-QSB for the period ending January 31, 2008 as
filed with the Securities and Exchange Commission on the date hereof (the
"Report"), I, William R. Colucci, Treasurer of the Company, certify, pursuant
to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:

    (1) The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and

    (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

Dated: March 17, 2008
                                  /s/ William R. Colucci
                                  ----------------------
                                  William R. Colucci, Treasurer
                                  BF Acquisition Group V, Inc.
[Federal Register Volume 82, Number 211 (Thursday, November 2, 2017)]
[Notices]
[Page 50858]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-23870]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-38-2017]


Foreign-Trade Zone (FTZ) 68--El Paso, Texas; Authorization of 
Production Activity; PGTEX USA, Inc.; (Fiber Glass Fabrics); El Paso, 
Texas

    On May 19, 2017, PGTEX USA, Inc. (PGTEX) submitted a notification 
of proposed production activity to the FTZ Board for its facility 
within FTZ 68--Site 3, in El Paso, Texas.
    The notification was processed in accordance with the regulations 
of the FTZ Board (15 CFR part 400), including notice in the Federal 
Register inviting public comment (82 FR 27797-27798, June 19, 2017). On 
September 18, 2017, the applicant was notified of the FTZ Board's 
decision that no further review of the activity is warranted at this 
time. The production activity described in the notification was 
authorized, subject to the FTZ Act and the FTZ Board's regulations, 
including Section 400.14, and further subject to a restriction 
requiring that foreign-status glass fiber rovings be admitted to the 
subzone in privileged foreign status (19 CFR 146.41).

    Dated: October 30, 2017.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2017-23870 Filed 11-1-17; 8:45 am]
BILLING CODE 3510-DS-P
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Baynon International Corp.
(the "Company") on Form 10-Q for the six months ended June 30, 2008 as
filed with the Securities and Exchange Commission on the date hereof
(the "Report"), I, Pasquale Catizone, Chief Executive Officer of the
Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
            (1) The Report fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
           (2) The information contained in the Report fairly presents,
in all material respects, the financial condition and result of
operations of the Company.

/s/Pasquale Catizone
-----------------------------
Pasquale Catizone
Chief Executive Officer

August 12, 2008


CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Baynon International Corp.
(the "Company") on Form 10-Q for the six months ended June 30, 2008 as
filed with the Securities and Exchange Commission on the date hereof
(the "Report"), I, Daniel Generelli, Chief Executive Officer of the
Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
            (1) The Report fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
           (2) The information contained in the Report fairly presents,
in all material respects, the financial condition and result of
operations of the Company.

/s/Daniel Generelli
-----------------------------
Daniel Generelli
Chief Financial Officer

August 12, 2008